ClinicalTrials.gg
WithdrawnNCT03130829Updated Aug 28, 2019

To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC

An interventional study of Oligo Fucoidan and Placebo in NSCLC Stage IV and NSCLC, Stage III, sponsored by Hi-Q Marine Biotech International, Ltd.. Withdrawn at 3 sites in Taiwan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-08-28.

Sponsored by Hi-Q Marine Biotech International, Ltd. · Not applicable, Interventional, and Supportive care

How we know

Why this study was withdrawn
target population is insufficient

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 519 studies in Carcinoma, Non-Small-Cell Lung with a site in Taiwan — 96 open to participants now, 201 under way, 90 of them phase 3. Carcinoma, Non-Small-Cell Lung · Taiwan.

Enrollment
477th of 479
0 · median 252
Started
2017
with 22 others
No phase
21 of 519
4 open now
Registered
227th of 519
by date

Among the 519 studies in Carcinoma, Non-Small-Cell Lung with a site in Taiwan, this one is the 477th largest by enrollment of the 479 interventional ones that give a count, is one of 23 that started in 2017, is one of 21 with no phase, and was the 227th registered.

Carcinoma, Non-Small-Cell Lung

7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

96 of the 519 studies in Carcinoma, Non-Small-Cell Lung with a site in Taiwan are open now. Recruiting first, the newest first:

91 more — sign in →

All 96 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 519 studies in Carcinoma, Non-Small-Cell Lung with a site in Taiwan, or all of them as a file.
02

Study summary

Primary Objectives:

To evaluate the Quality of Life (QoL) score of adding oral Oligo Fucoidan to platinum-based chemotherapy in comparison with placebo in subjects with Non-Small Cell Lung Cancer (NSCLC).

Secondary Objectives:

To assess the progression-free survival (PFS) and objective response rate (ORR) of adding oral Oligo Fucoidan to platinum-based chemotherapy in comparison with placebo in subjects with NSCLC.

Read the detailed description

This is a pilot, randomized, double-blind, multicenter study to evaluate the QoL score of Oligo Fucoidan plus platinum-based chemotherapy versus placebo plus platinum-based chemotherapy in subjects with NSCLC. Subjects will be randomized in a 1:1 ratio to receive 4.4 g BID of Oligo Fucoidan or placebo BID. Subject randomization will be stratified by NSCLC disease stage (stage III and stage IV) and platinum-based drug (cisplatin and carboplatin).

This is a two-part study. The study treatment will be planned as follow:

  1. Part I (Platinum-based Treatment Phase): Oligo Fucoidan/placebo in combination with 4\~6 cycles of platinum-based chemotherapy;
  2. Part II (Extension Phase): Continuous Oligo Fucoidan/placebo treatment after subject completed platinum-based chemotherapy.

The total study treatment duration of investigational product from Part I to Part II will be 6 months.

Dosing of oral Oligo Fucoidan/placebo will begin on Study Day -2, 2 days prior to the start of the platinum-based chemotherapy regimen, and will continue twice a day (BID) through the following 6-months treatment period, which includes platinum-based treatment phase and extension phase, if there's no treatment interruption. All subjects will receive platinum-based IV infusion starting on Day 1 of each cycle, 3 weeks per cycle. Subjects will continue to receive Oligo Fucoidan/placebo for 6 months until develop of treatment toxicity which in the Investigator's opinion prohibits for further therapy, or until radiographic progression of disease. Subjects who experience toxicities due to chemotherapy may require a delay in the dosing schedule or a dose modification. Should a subject not receive platinum-based chemotherapy on a scheduled cycle, a rescheduled cycle will be designated when chemotherapy is reintroduced, but no more than 2 weeks delay.

The visit for subjects who have completed platinum-based treatment phase will be considered as the End of Part I Visit (end of platinum-based treatment phase). The visit for subjects who have completed 6-months treatment period (Part I \& Part II) will be considered as the End of Treatment (EOT) Visit. It is preferable that EOT Visit procedures will be conducted for subjects prior to the initiation of another anticancer therapy.

Radiographic tumor assessments will be conducted at screening period, Cycle 4, End of Platinum-based Treatment Phase, and EOT. Radiographic information will be collected according to the Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1.

Toxicities will be graded at each study visit according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03.

Quality of life assessment as measured by the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30) as well as health-related quality of life questionnaire designed by the National Health Research Institutes (NHRI), NHRI QLQ-TCM, based on traditional Chinese medicine (TCM) perspective. Both of them will be performed at Study Day -2, Day 8 of Cycle 1, Day 1 of Cycle 3 \& Cycle 5, and End of Platinum-based Treatment Phase.

03

Conditions studied

  • NSCLC Stage IV
  • NSCLC, Stage III

Keywords

  • NSCLC
  • QoL
  • Fucoidan
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects must be ≥ 20 years of age, inclusive, at time of screening.
  • > 12 weeks.
  • Subject must have or histologically confirmed NSCLC. Subjects with mixed histology tumors will be eligible. If cytology is used for diagnosis, the sample must be unequivocally NSCLC.
  • Subject has Stage III or IV NSCLC disease at the time of screening.
  • Subject is not amenable to surgical resection or radiation with curative intent and have not received chemotherapy for their NSCLC, no matter it is new diagnosis or relapse.
  • Subject is planned to receive triweekly platinum-based chemotherapy regimen prior to randomization. (Platinum dose for cisplatin is 51\~80 mg/m2, or carboplatin at AUC 4\~6)
  • Subject must have at least 1 measurable tumor lesion, not previously irradiated, as defined by (version 1.1).
  • Subject must have no history of or evidence of CNS tumors at screening assessment..
  • Subject must have an (ECOG) Performance Score of 0-2.
  • Subject must be able to take oral medication.
  • Subject must have adequate bone marrow, renal and hepatic function as follows:

    • (ANC) ≥ 1,500/mm3 (1.5 × 109/L);
    • ≥ 100,000/mm3 (100 × 109/L);
    • ≥ 9.0 g/dL (5.6 mmol/L);
    • Serum creatinine concentration within the normal range (according to the standard value of each hospital);
    • Hepatic function: and ALT ≤ 2.5 times unless liver are present, then AST and ALT \< 5.0 times upper limit of normal; ≤ 1.5 times upper limit of normal (subjects with Gilbert's Syndrome may have a bilirubin ≤ 3.0 times upper limit of normal).
  • Female and male patients of and at the risk of pregnancy must agree to use at least one of highly effective method throughout the study.
  • Subject must be capable of understanding and complying with parameters as outlined in the protocol and able to sign inform consent.

Exclusion criteria

Exclusion Criteria:

  • Subject has a known to Fucoidan, platinum compounds and all other drug component of current chemotherapy.
  • Subject has peripheral neuropathy ≥ grade 2.
  • Subject has a history of seizure within 12 months prior to study entry.
  • Subject has received more or equal to biomarker-targeted therapy.
  • Subject has received herbal remedies for cancer treatment, non-prescription anti-cancer supplements for cancer treatment, or traditional Chinese medicine with an approved anti-cancer indication within 2 weeks prior to randomization.
  • Subject is undergone or planned to receive curative radiation therapy prior to randomization and during study. (The palliative radiation therapy such as for bony lesions is allowed, but irradiate on target lesion will not be allowed.)
  • Subject has and uncontrolled major medical condition(s) including but not limited to:

    • Uncontrolled nausea/vomiting/diarrhea;
    • Active uncontrolled infection;
    • Symptomatic congestive heart failure;
    • Unstable angina pectoris or cardiac arrhythmia;
    • Psychiatric illness/social situation that would limit compliance with study requirements;
    • History of gross hemoptysis;
    • Any medical condition, which in the opinion of the Investigator, places the subject at an unacceptably high risk for toxicities.
  • Subject is pregnant or lactating.
  • Subject participates in study using an drug within 30 days prior to screening.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Oligo Fucoidan

    Oligo Fucoidan 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.

    Dietary Supplement: Oligo Fucoidan

  • Placebo comparator
    Placebo

    Placebo 4.4 g, sachet, oral, twice a day from Study Day -2 to End of Treatment.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementOligo Fucoidan

    Oral, twice daily

  • Dietary supplementPlacebo

    Oral, twice daily

06

What researchers measure

Primary outcomes

  1. Quality of Life (QoL)

    Comparison of the QoL score changes from Study Day -2 to End of Platinum-based Treatment Phase between Oligo Fucoidan and placebo groups in intent to treat set (ITT) via the QoL questionnaire

    Time frame: Day -2 to complete of Platinum-based Treatment Phase(week18)

Secondary outcomes

  1. Quality of Life (QoL)

    Comparison of the QoL score changes from Study Day -2 to C1D8, C3D1, and C5D1 of Platinum-based Treatment Phase between Oligo Fucoidan and placebo groups in intent to treat set (ITT) via the QoL questionnaire.

    Time frame: tinumDay -2 to C1D8(week1), Cycle 3(week9), and Cycle 5(week15) of Platinum-based Treatment Phase

  2. Progression-Free Survival (PFS)

    Progression-Free Survival will be evaluated according to radiographic progression per RECIST version 1.1 and survival information (death)

    Time frame: Screening (baseline), Cycle 4(week12), complete of Platinum-based Treatment Phase(week18), EOT(week24), and 3 months post-treatment follow up if required

  3. Objective Response Rate (ORR)

    Objective Response Rate will be evaluated using measurements according to RECIST version 1.1

    Time frame: Screening (baseline), Cycle 4(week12), complete of Platinum-based Treatment Phase(week18), EOT(week24), and 3 months post-treatment follow up if required

  4. Change of Cytokines

    To evaluate the changes of cytokine

    Time frame: Screening (baseline), Cycle 3 (week 9), and complete of Platinum-based Treatment Phase(week18)

07

Study locations

3 sites
  • Shuang Ho Hospital
    New Taipei City, 235, Taiwan
  • Wan-Fang Hospital
    Taipei, 116, Taiwan
  • Taipei Medical University Hospital
    Taipei, Taiwan
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2017; primary completion for Feb 2020, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2017
First posted
Apr 27, 2017
StartEst.
Apr 26, 2017
Primary completionEst.
Feb 28, 2020
CompletionEst.
Apr 30, 2020
Last update
Aug 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03130829
Lead sponsor
Hi-Q Marine Biotech International, Ltd.
Responsible party
Sponsor
First posted
Apr 27, 2017
Start date
Apr 26, 2017 (estimated)
Primary completion
Feb 28, 2020 (estimated)
Completion
Apr 30, 2020 (estimated)
Last update
Aug 28, 2019

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oligo-fucoidan

Start the discussion